43,087 results
Search Results
2. Citrus Fruits–Leaves Diseases Detection and Classification with Optimized Deep CNN
- Author
-
Saini, Ashok Kumar, Bhatnagar, Roheet, Srivastava, Devesh Kumar, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Nagar, Atulya K., editor, Jat, Dharm Singh, editor, Mishra, Durgesh, editor, and Joshi, Amit, editor
- Published
- 2024
- Full Text
- View/download PDF
3. Call for Papers: Special Issue on Mitochondrial DNA in Health and Disease.
- Author
-
Cali T and Brini M
- Subjects
- Humans, Mitochondria genetics, Mitochondria metabolism, DNA, Mitochondrial genetics, Disease etiology, Editorial Policies, Mitochondria pathology, Periodicals as Topic
- Published
- 2019
- Full Text
- View/download PDF
4. Scientific impact increases when researchers publish in open access and international collaboration: A bibliometric analysis on poverty-related disease papers.
- Author
-
Breugelmans JG, Roberge G, Tippett C, Durning M, Struck DB, and Makanga MM
- Subjects
- Africa South of the Sahara, Bibliometrics, Databases, Bibliographic, Developing Countries, Europe, Humans, Internationality, Journal Impact Factor, Regression Analysis, Research Personnel, Disease, Open Access Publishing, Poverty
- Abstract
Background: The European & Developing Countries Clinical Trials Partnership (EDCTP), like many other research funders, requires its grantees to make papers available via open access (OA). This article investigates the effect of publishing in OA journals and international collaboration within and between European and sub-Saharan African countries on citation impact and likelihood of falling into the top 1% and top 10% most cited papers in poverty-related disease (PRD) research., Methods: Disease-specific research publications were identified in the Web of Science™ and MEDLINE using Medical Subject Heading (MeSH) terms. Data on the open accessibility of scientific literature were derived from 1science oaFindr. Publication data, including relative citation counts, were extracted for 2003-2015. Regression models were applied to quantify the relationship between relative citations and presence in the 1% and top 10% most cited papers versus OA and international collaboration., Results: The results show that since 2003 papers on PRDs have become increasingly available in OA. Among all PRD areas, malaria research is most frequently published in OA and in international collaboration. The adjusted regression analyses show that holding other factors constant, publishing research in OA and in international collaboration has a significant and meaningful citation advantage over non-OA or non-international collaborative research. Publishing papers as part of a European-wide or European- sub-Saharan African collaboration increases research impact. In contrast, such collaboration advantage is not observed for research output involving sub-Saharan Africa only which seems to decrease research impact., Conclusions: Our results indicate that there is a real, measurable citation advantage for publishing PRD research in OA and international collaboration. However, the international collaboration advantage seems to be region-specific with increased research impact for European-wide and European-sub-Saharan African collaborations but a decrease in research impact of collaborations confined to sub-Saharan African research institutions. Further research is required to further verify this finding and to understand the underlying factors related to this observed decrease in research impact. To target future research capacity building activities in sub-Saharan Africa it is important to assess whether the observed decreased impact reflects the scientific competencies and geographic distribution of individual researchers or institutional-, national- or funder-specific research requirements., Competing Interests: JGB and MMM have no competing interests to declare. CT, GR, MD and DBS have the following interests to declare: CT, GR, MD and DBS are employed by Science-Metrix. Financial support was provided by Science-Metrix for the manuscript preparation (over and above the contracted study) in the form of salaries for CT, GR, MD and DBS. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
- Published
- 2018
- Full Text
- View/download PDF
5. COVID-19 Detection in the Images of Chest CT Scan Using K-NN in Comparison with NB Classifier to Improve the Accuracy
- Author
-
Govind, Y. B. Dinesh, Vijayalakshmi, B. Anitha, Filipe, Joaquim, Editorial Board Member, Ghosh, Ashish, Editorial Board Member, Prates, Raquel Oliveira, Editorial Board Member, Zhou, Lizhu, Editorial Board Member, Shaw, Rabindra Nath, editor, Paprzycki, Marcin, editor, and Ghosh, Ankush, editor
- Published
- 2023
- Full Text
- View/download PDF
6. Hybridizing Convolution Neural Networks to Improve the Accuracy of Plant Leaf Disease Classification
- Author
-
Nerkar, Bhavana, Talbar, Sanjay, Filipe, Joaquim, Editorial Board Member, Ghosh, Ashish, Editorial Board Member, Prates, Raquel Oliveira, Editorial Board Member, Zhou, Lizhu, Editorial Board Member, Santosh, K. C., editor, and Gawali, Bharti, editor
- Published
- 2021
- Full Text
- View/download PDF
7. The Methodology of Risk Assessment of the Technogenic Impact of Construction Enterprises on the Environment
- Author
-
Guschin, I. A., Ezhova, O. N., di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Klyuev, Sergey Vasil'yevich, editor, and Klyuev, Alexander Vasil'yevich, editor
- Published
- 2021
- Full Text
- View/download PDF
8. Call for papers: aging versus disease.
- Author
-
Newman AB and Ferrucci L
- Subjects
- Animals, Humans, Aging, Disease etiology
- Published
- 2009
- Full Text
- View/download PDF
9. Classification of IRIS Recognition Based on Deep Learning Techniques
- Author
-
Goyal, Mukta, Krishnamurthi, Rajalakshmi, Varma, Aparna, Khare, Ishita, Filipe, Joaquim, Editorial Board Member, Ghosh, Ashish, Editorial Board Member, Kotenko, Igor, Editorial Board Member, Prates, Raquel Oliveira, Editorial Board Member, Zhou, Lizhu, Editorial Board Member, Batra, Usha, editor, Roy, Nihar Ranjan, editor, and Panda, Brajendra, editor
- Published
- 2020
- Full Text
- View/download PDF
10. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society.
- Author
-
Allison DB, Downey M, Atkinson RL, Billington CJ, Bray GA, Eckel RH, Finkelstein EA, Jensen MD, and Tremblay A
- Subjects
- Discrimination, Psychological, Dissent and Disputes, Humans, Disease, Obesity, Terminology as Topic
- Published
- 2008
- Full Text
- View/download PDF
11. Frontiers in glycomics: bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006).
- Author
-
Packer NH, von der Lieth CW, Aoki-Kinoshita KF, Lebrilla CB, Paulson JC, Raman R, Rudd P, Sasisekharan R, Taniguchi N, and York WS
- Subjects
- Animals, Computational Biology methods, Computational Biology standards, Glycomics methods, Glycomics standards, Guidelines as Topic, Humans, National Institutes of Health (U.S.), United States, Biomarkers analysis, Biomarkers chemistry, Carbohydrates chemistry, Computational Biology trends, Disease, Focus Groups, Glycomics trends
- Abstract
Key issues relating to glycomics research were discussed after the workshop entitled "Frontiers in Glycomics: Bioinformatics and Biomarkers in Disease" by two focus groups nominated by the organizers. The groups focused on two themes: (i) glycomics as the new frontier for the discovery of biomarkers of disease and (ii) requirements for the development of informatics for glycomics and glycobiology. The mandate of the focus groups was to build consensus on these issues and develop a summary of findings and recommendations for presentation to the NIH and the greater scientific community. A list of scientific priorities was developed, presented, and discussed at the workshops. Additional suggestions were solicited from workshop participants and collected using the workshop mailing list. The results are summarized in this White Paper, authored by the co-chairs of the focus groups.
- Published
- 2008
- Full Text
- View/download PDF
12. Exploring the continuum: medical information to effective clinical practice. Paper II. Towards aetiology-centred clinical practice.
- Author
-
Genuis SJ and Genuis SK
- Subjects
- Chronic Disease, Humans, Diffusion of Innovation, Disease etiology, Health Promotion, Patient-Centered Care, Practice Patterns, Physicians'
- Abstract
Contemporary clinical practice increasingly functions within a disease management paradigm aimed at finding and implementing therapeutic interventions that demonstrate efficacy in clinical trials. Disease prevention, elucidation of illness aetiology and proactive health promotion have taken a back seat. Current clinical care often includes a 'fast-food' type of medical encounter, which frequently neglects disease causality. The medical community is presently challenged by unique administrative and professional adversities as well as undue commercial influence; these factors contribute to a lethargic response to escalating rates of chronic illness and to mainstream medicine's relative inattention to emerging research about disease aetiology. Individual medical practitioners and the medical establishment must strategically seek to advance patient health and maintain professional relevancy by a renewed emphasis on the following principles: patient-based clinical care, aetiology-centred medicine, and proactive health promotion.
- Published
- 2006
- Full Text
- View/download PDF
13. Diagnosis of Arthritis Using K-Nearest Neighbor Approach
- Author
-
Kaur, Rupinder, Madaan, Vishu, Agrawal, Prateek, Barbosa, Simone Diniz Junqueira, Editorial Board Member, Filipe, Joaquim, Editorial Board Member, Ghosh, Ashish, Editorial Board Member, Kotenko, Igor, Editorial Board Member, Zhou, Lizhu, Editorial Board Member, Yuan, Junsong, Founding Editor, Luhach, Ashish Kumar, editor, Jat, Dharm Singh, editor, Hawari, Kamarul Bin Ghazali, editor, Gao, Xiao-Zhi, editor, and Lingras, Pawan, editor
- Published
- 2019
- Full Text
- View/download PDF
14. [Paper electrophoretic studies of subdural effusions in children].
- Author
-
KOCH F and SCHMIDT GW
- Subjects
- Blood Proteins, Blood Transfusion complications, Disease, Electrophoresis, Paper, Meninges, Proteins metabolism, Subdural Effusion
- Published
- 1957
15. Localization of serum leucine aminopeptidase activity by paper electrophoresis.
- Author
-
SMITH EE, PINEDA EP, and RUTENBURG AM
- Subjects
- Biliary Tract, Biliary Tract Diseases, Disease, Electrophoresis, Electrophoresis, Paper, Endopeptidases, Leucine, Leucyl Aminopeptidase, Pancreas, Pancreatic Diseases, Peptide Hydrolases blood
- Published
- 1962
- Full Text
- View/download PDF
16. [Paper electrophoresis in arthrosis of the knee. (A study of the protein composition of blood and synovia)].
- Author
-
HOULI J and de SOUZA M
- Subjects
- Humans, Blood Proteins, Disease, Electrophoresis, Paper, Knee, Knee Joint, Proteins metabolism, Synovial Fluid
- Published
- 1960
17. [Use of paper microelectrophoresis in the study of blood proteins in patients with muscular diseases].
- Author
-
LOWENTHAL A and VAN SANDE M
- Subjects
- Blood Proteins, Disease, Electrophoresis, Muscles, Muscular Diseases, Paper
- Published
- 1954
18. Some notes on the paper by M. Tushinskaya and Yu. Urinson, "The influence of the spleen on hemopoiesis.
- Author
-
YANOVSKII DN
- Subjects
- Humans, Disease, Hematopoiesis physiology, Leadership, Paper, Spleen, Splenic Diseases
- Published
- 1961
19. [The aspects of 2-dimension paper chromatography of amino acids of the serum and urine of French Algerian Moslems presenting the phenomenon of myoedema].
- Author
-
LACROIX AC and MONIER JC
- Subjects
- Humans, Amino Acids metabolism, Chromatography, Paper, Disease, Edetic Acid metabolism, Metabolic Diseases, Muscles, Muscular Diseases, Nutrition Disorders metabolism, Nutritional Status
- Published
- 1961
20. [18th Congress of Ophthalmologists, Prag, December 11-14, 1952; Collected papers about the cornea].
- Subjects
- Humans, Cornea, Corneal Diseases, Disease, Ophthalmology, Paper, Physicians
- Published
- 1953
21. [Urinary amino acids in myopathies with paper chromatography of distribution].
- Author
-
DI PERRI T, ZALAFFI RC, and RAVENNI G
- Subjects
- Humans, Amino Acids urine, Chromatography, Paper, Disease, Muscles, Muscular Diseases
- Published
- 1958
22. [Therapy of dentin hyperesthesia; supplementary remarks on H. E. Zichner's paper].
- Author
-
HEROD W
- Subjects
- Humans, Dentin, Disease, Hyperesthesia, Paper
- Published
- 1955
23. [On G. Roux's paper on pelvic pains in women].
- Author
-
LABRY R and MATHIEU J
- Subjects
- Female, Humans, Disease, Paper, Pelvic Pain, Pelvis
- Published
- 1957
24. [Paper chromatographic studies of progressive muscular dystrophy as well as of other myopathies].
- Author
-
SCHONENBERG H
- Subjects
- Humans, Amino Acids urine, Chromatography, Chromatography, Paper, Disease, Muscles, Muscular Diseases, Muscular Dystrophies urine, Urine
- Published
- 1955
- Full Text
- View/download PDF
25. Paper electrophoresis of hemoglobin as a practical method of differentiating various types of sickle cell disease and of hemoglobin C trait.
- Author
-
SCHNEIDER RG
- Subjects
- Hemoglobin, Sickle, Humans, Anemia, Anemia, Sickle Cell diagnosis, Diagnosis, Differential, Disease, Electrophoresis, Electrophoresis, Paper, Hemoglobin C, Hemoglobinopathies, Hemoglobins analysis, Muscles, Muscular Diseases, Thigh blood supply
- Published
- 1953
26. [Paper electrophoresis of plasma proteins in the hemoblastosis].
- Author
-
DIAZ-RUBIO M and SEGOVIA F
- Subjects
- Blood Proteins, Disease, Electrophoresis, Paper, Hematopoietic System
- Published
- 1956
27. A water-miscible oil impregnated paper. Its use in fissured heel management.
- Author
-
PRENTICE H
- Subjects
- Disease, Disease Management, Fertilization, Heel, Oils therapy, Paper
- Published
- 1962
28. [Comments on MA Nogaller's response to my paper "On the So-Called Functional Diseases"].
- Author
-
Sarkisov DS
- Subjects
- Humans, Disease etiology
- Published
- 1996
29. Diagnostic approach to neonatal and infantile cholestasis: A position paper by the SIGENP liver disease working group
- Author
-
Maurizio Fuoti, Mara Cananzi, Giulia Paolella, Manila Candusso, Paola Francalanci, Lidia Monti, Emanuele Nicastro, Lorenzo D'Antiga, Carlo Dionisi Vici, Michele Pinon, Lorenza Matarazzo, Irene Degrassi, P. Gaio, Angelo Di Giorgio, Giusy Ranucci, Pier Luigi Calvo, Giuseppe Indolfi, Claudia Mandato, Fabio Mosca, Pietro Vajro, Maria Pia Bondioni, Maria Iascone, Maria Grazia Clemente, Federica Nuti, Marco Sciveres, Jean de Ville de Goyet, Claudia Della Corte, Marco Spada, Chiara Grimaldi, Federica Ferrari, Gabriella Nebbia, Giuseppe Maggiore, Fabio Fusaro, Daniele Serranti, Daniele Alberti, Fabiola Di Dato, Paola Roggero, Raffaele Iorio, and Giovanni Boroni
- Subjects
Male ,medicine.medical_specialty ,Genetic liver disease ,Alagille syndrome ,Biliary atresia ,Diagnosis ,Inborn errors of metabolism ,Jaundice ,Monogenic liver disease ,Newborn ,Female ,Gastroenterology ,Humans ,Infant ,Infant, Newborn ,Cholestasis ,Evidence-Based Medicine ,Infant, Newborn, Diseases ,Practice Guidelines as Topic ,Diseases ,Disease ,Liver disease ,Epidemiology ,medicine ,Intensive care medicine ,Hepatology ,business.industry ,medicine.disease ,Etiology ,Position paper ,medicine.symptom ,business - Abstract
Neonatal and infantile cholestasis (NIC) can represent the onset of a surgically correctable disease and of a genetic or metabolic disorder worthy of medical treatment. Timely recognition of NIC and identification of the underlying etiology are paramount to improve outcomes. Upon invitation by the Italian National Institute of Health (ISS), an expert working grouped was formed to formulate evidence-based positions on current knowledge about the diagnosis of NIC. A systematic literature search was conducted to collect evidence about epidemiology, etiology, clinical aspects and accuracy of available diagnostic tests in NIC. Evidence was scored using the GRADE system. All recommendations were approved by a panel of experts upon agreement of at least 75% of the members. The final document was approved by all the panel components. This position document summarizes the collected statements and defines the best-evidence diagnostic approach to cholestasis in the first year of life.
- Published
- 2022
30. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper
- Author
-
Patrizia Bonadonna, Emilio Alvarez-Cuesta, Adile Berna Dursun, Soledad Sanchez Sanchez, Mariana Castells, Josefina Cernadas, Mauro Pagani, Hamadi Sahar, Anca M. Chiriac, Ricardo Madrigal-Burgaleta, and Sevim Bavbek
- Subjects
Drug ,medicine.medical_specialty ,Allergy ,media_common.quotation_subject ,medicine.medical_treatment ,Immunology ,Provocation test ,Drug allergy ,Antineoplastic Agents ,Disease ,Drug Hypersensitivity ,Neoplasms ,Humans ,Immunology and Allergy ,Medicine ,Intensive care medicine ,Anaphylaxis ,Skin Tests ,media_common ,Desensitization (medicine) ,business.industry ,medicine.disease ,Desensitization, Immunologic ,Position paper ,business - Abstract
Chemotherapeutic drugs have been widely used in the treatment of cancer disease for about 70 years. The development of new treatments has not hindered their use, and oncologists still prescribe them routinely, alone or in combination with other antineoplastic agents. However, all chemotherapeutic agents can induce hypersensitivity reactions (HSRs), with different incidences depending on the culprit drug. These reactions are the third leading cause of fatal drug-induced anaphylaxis in the United States. In Europe, deaths related to chemotherapy have also been reported. In particular, most reactions are caused by platinum compounds, taxanes, epipodophyllotoxins and asparaginase. Despite their prevalence and relevance, the ideal pathways for diagnosis, treatment and prevention of these reactions are still unclear, and practice remains considerably heterogeneous with vast differences from center to center. Thus, the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology organized a task force to provide data and recommendations regarding the allergological work-up in this field of drug hypersensitivity reactions. This position paper aims to provide consensus on the investigation of HSRs to chemotherapeutic drugs and give practical recommendations for clinicians that treat these patients, such as oncologists, allergologists and internists. Key sections cover risk factors, pathogenesis, symptoms, the role of skin tests, in vitro tests, indications and contraindications of drug provocation tests and desensitization of neoplastic patients with allergic reactions to chemotherapeutic drugs. Statements, recommendations and unmet needs were discussed and proposed at the end of each section.
- Published
- 2021
31. Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: a position paper from the EU-CardioRNA COST action CA17129
- Author
-
Stephanie Bezzina Wettinger, Maarten Vanhaverbeke, Costanza Emanueli, Johannes Grillari, Rosienne Farrugia, Monika Bartekova, Barbora Kalocayova, Soumaya Ben-Aicha, EU-CardioRNA Cost Action Ca, Markus Scholz, R. Attard, Yvan Devaux, Matthias Hackl, Fabio Martelli, David de Gonzalo-Calvo, Timo Brandenburger, and EU-CardioRNA COST Action (CA17129)
- Subjects
Cardiovascular system -- Diseases ,Physiology ,business.industry ,RNA ,Genomics ,Disease ,Cardiovascular system -- Diseases -- Diagnosis ,Bioinformatics ,medicine.disease ,Transcriptome ,Physiology (medical) ,Heart failure ,Cardiovascular system -- Diseases -- Treatment ,Gene expression ,medicine ,Biomarker (medicine) ,Position paper ,Cardiology and Cardiovascular Medicine ,business - Abstract
Despite significant advances in the diagnosis and treatment of cardiovascular diseases, recent calls have emphasized the unmet need to improve precision-based approaches in cardiovascular disease. Although some studies provide preliminary evidence of the diagnostic and prognostic potential of circulating coding and non-coding RNAs, the complex RNA biology and lack of standardization have hampered the translation of these markers into clinical practice. In this position paper of the CardioRNA COST action CA17129, we provide recommendations to standardize the RNA development process in order to catalyse efforts to investigate novel RNAs for clinical use. We list the unmet clinical needs in cardiovascular disease, such as the identification of high-risk patients with ischaemic heart disease or heart failure who require more intensive therapies. The advantages and pitfalls of the different sample types, including RNAs from plasma, extracellular vesicles, and whole blood, are discussed in the sample matrix, together with their respective analytical methods. The effect of patient demographics and highly prevalent comorbidities, such as metabolic disorders, on the expression of the candidate RNA is presented and should be reported in biomarker studies. We discuss the statistical and regulatory aspects to translate a candidate RNA from a research use only assay to an in-vitro diagnostic test for clinical use. Optimal planning of this development track is required, with input from the researcher, statistician, industry, and regulatory partners., peer-reviewed
- Published
- 2021
32. Vaccination of patients with allergic disease against novel coronavirus infection: position paper of the Russian Association of Allergology and Clinical Immunology
- Author
-
O M Kurbacheva, N V Shartanova, Natalya I. Ilyina, Elena A. Latysheva, Musa R. Khaitov, Tatiana V. Latysheva, Evgeniya V. Nazarova, Natalia M. Nenasheva, and Elena S. Fedenko
- Subjects
Pediatrics ,medicine.medical_specialty ,Allergy ,Clinical immunology ,business.industry ,General Medicine ,Disease ,medicine.disease_cause ,medicine.disease ,Virus ,Vaccination ,Pandemic ,Medicine ,Position paper ,business ,Coronavirus - Abstract
One of the key tasks of the previous year is to stop the spread of coronavirus disease (COVID-19), which became a pandemic that led to the deaths of more than 4 million people worldwide and more than 140 thousand deaths in Russia. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (2019-nCoV) virus of the coronavirus family. Vaccination plays a leading role in ending the pandemic. Currently, five vaccines against COVID-19 have been registered in Russia, namely, Sputnik V, Sputnik light, EpiVacCorona, EpiVacCorona-Н, and СoviVak. The short follow-up period and absence of randomized placebo-controlled trials of COVID-19 vaccines in certain patients with chronic diseases lead to several questions about the effectiveness/safety of vaccination in these patients. Given the wide spread of allergic diseases and the heterogeneity of patients with allergopathology, experts of the Russian Association of Allergology and Clinical Immunology have developed and approved a position paper on vaccination of patients with allergopathology.
- Published
- 2021
33. Screening for depression in the medically ill. The future of paper and pencil tests.
- Author
-
Meakin CJ
- Subjects
- Depressive Disorder psychology, Female, Humans, Male, Reproducibility of Results, Surveys and Questionnaires, Depressive Disorder diagnosis, Disease psychology, Personality Inventory standards, Psychiatric Status Rating Scales standards
- Abstract
Paper and pencil screening tests for depression have never become widely used in the medically ill, despite consensus that a sizeable pool of depression exists in this population. The performance of several self-rating scales in these patients is reviewed, demonstrating that satisfactory screening of depression as defined by standard case criteria can be achieved. It is proposed that it is primarily the absence of clear guidelines for treatment to be used in conjunction with these scales which will make clinicians sceptical of their value. Treatment validation of case criteria is required to demonstrate that screening for depression in medical patients is worthwhile.
- Published
- 1992
- Full Text
- View/download PDF
34. One Health: EAACI Position Paper on coronaviruses at the human‐animal interface, with a specific focus on comparative and zoonotic aspects of SARS‐CoV‐2
- Author
-
Erika Jensen-Jarolim, Jozef Janda, Anna D. J. Korath, Isabella Pali-Schöll, Wojciech Feleszko, Milena Sokolowska, Eva Untersmayr, Ahmed Adel Seida, Katrin Hartmann, Ioana Agache, University of Zurich, and Pali‐Schöll, Isabella
- Subjects
Eaaci Position Paper ,Immunology ,coronavirus ,610 Medicine & health ,Disease ,medicine.disease_cause ,Quality of life (healthcare) ,10183 Swiss Institute of Allergy and Asthma Research ,Environmental health ,Pandemic ,medicine ,Animals ,Humans ,Immunology and Allergy ,One Health ,Pandemics ,Coronavirus ,disease transmission ,(reverse) zoonosis ,2403 Immunology ,SARS-CoV-2 ,Transmission (medicine) ,COVID-19 ,Outbreak ,companion animals and pets ,Geography ,2723 Immunology and Allergy ,Quality of Life ,Position paper - Abstract
The latest outbreak of a coronavirus disease in 2019 (COVID‐19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), evolved into a worldwide pandemic with massive effects on health, quality of life, and economy. Given the short period of time since the outbreak, there are several knowledge gaps on the comparative and zoonotic aspects of this new virus. Within the One Health concept, the current EAACI position paper dwells into the current knowledge on SARS‐CoV‐2’s receptors, symptoms, transmission routes for human and animals living in close vicinity to each other, usefulness of animal models to study this disease and management options to avoid intra‐ and interspecies transmission. Similar pandemics might appear unexpectedly and more frequently in the near future due to climate change, consumption of exotic foods and drinks, globe‐trotter travel possibilities, the growing world population, the decreasing production space, declining room for wildlife and free‐ranging animals, and the changed lifestyle including living very close to animals. Therefore, both the society and the health authorities need to be aware and well prepared for similar future situations, and research needs to focus on prevention and fast development of treatment options (medications, vaccines).
- Published
- 2021
35. Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology
- Author
-
Patricia de Sequera, Rafael Santamaria, Javier Díez, Alberto Ortiz, and Juan F. Navarro-González
- Subjects
Nephrology ,medicine.medical_specialty ,Enfermedad cardiovascular ,030232 urology & nephrology ,Psychological intervention ,Specialty ,Disease ,030204 cardiovascular system & hematology ,Subspecialty ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Renal Insufficiency, Chronic ,Enfermedad renal crónica ,business.industry ,medicine.disease ,Diseases of the genitourinary system. Urology ,Cardio-nefrología ,Cardiovascular Diseases ,Family medicine ,Medicina cardiorenal ,Position paper ,Professional association ,RC870-923 ,business ,Kidney disease - Abstract
Patients with the dual burden of chronic kidney disease (CKD) and cardiovascular disease (CVD) experience unacceptably high rates of morbidity and mortality, which also entail unfavorable effects on healthcare systems. Currently, concerted efforts to identify, prevent and treat CVD in CKD patients are lacking at the institutional level, with emphasis still being placed on individual specialty views on this topic. The authors of this position paper endorse the need for a dedicated interdisciplinary team of subspecialists in cardio-nephrology that manages appropriate clinical interventions across the inpatient and outpatient settings. There is a critical need for training programs, guidelines and best clinical practice models, and research funding from nephrology, cardiology and other professional societies, to support the development of the subspecialty of cardio-nephrology. This position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology (S.E.N.) is intended to be the starting point to develop the subspecialty of cardio-nephrology within the S.E.N.. The implementation of the subspecialty in day-to-day nephrological practice will help to diagnose, treat, and prevent CVD in CKD patients in a precise, clinically effective, and health cost-favorable manner. Resumen: Los pacientes con enfermedad renal crónica (ERC) que presentan enfermedad cardiovascular (ECV) tienen índices de morbilidad y mortalidad inaceptablemente elevados, que impactan desfavorablemente sobre los sistemas de salud. En la actualidad, se requieren actuaciones multidisciplinares para identificar, prevenir y tratar la ECV en los pacientes con ERC, debiendo pues superarse la época de las actuaciones de las especialidades individuales. Los autores de este artículo respaldan la necesidad de un equipo interdisciplinar de subespecialistas en cardionefrología que gestione las intervenciones clínicas adecuadas en el entorno hospitalario y en el ambulatorio. Existe una gran necesidad de programas de formación, de guías y modelos de práctica clínica, y de fondos para la investigación en las sociedades de nefrología, cardiología y otras, para apoyar el desarrollo de la subespecialidad de cardio-nefrología. Este documento de opinión del comité coordinador del Grupo de Trabajo de Medicina Cardiorenal de la Sociedad Española de Nefrología (S.E.N.) pretende ser el inicio del desarrollo de la subespecialidad de Cardionefrología en el marco de la S.E.N. La implementación de la subespecialidad en la práctica nefrológica diaria contribuirá a diagnosticar, tratar y prevenir la ECV en los pacientes con ERC de una manera precisa, clínicamente efectiva y sanitariamente rentable.
- Published
- 2021
36. Report of the COMA panel on dietary sugars and human disease: discussion paper.
- Author
-
Yudkin J
- Subjects
- Animals, Humans, United Kingdom, Dietary Carbohydrates adverse effects, Disease, Sucrose adverse effects
- Published
- 1990
- Full Text
- View/download PDF
37. Examining guidelines and new evidence in oncology nutrition: a position paper on gaps and opportunities in multimodal approaches to improve patient care
- Author
-
Carla M. Prado, Michael D. Bastasch, Shila M. Newman, Maureen Gardner, Chelsia Gillis, Anthony D. Sung, Martin Chasen, Suayib Yalcin, Abby C. Sauer, Suzanne Dixon, Refaat Hegazi, and Alessandro Laviano
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Nursing research ,Pain medicine ,Prehabilitation ,Disease ,medicine.disease ,Malnutrition ,Quality of life (healthcare) ,Multidisciplinary approach ,Internal medicine ,medicine ,Position paper ,business - Abstract
Malnutrition, muscle loss, and cachexia are prevalent in cancer and remain key challenges in oncology today. These conditions are frequently underrecognized and undertreated and have devastating consequences for patients. Early nutrition screening/assessment and intervention are associated with improved patient outcomes. As a multifaceted disease, cancer requires multimodal care that integrates supportive interventions, specifically nutrition and exercise, to improve nutrient intake, muscle mass, physical functioning, quality of life, and treatment outcomes. An integrated team of healthcare providers that incorporates societies’ recommendations into clinical practice can help achieve the best possible outcomes. A multidisciplinary panel of experts in oncology, nutrition, exercise, and medicine participated in a 2-day virtual roundtable in October 2020 to discuss gaps and opportunities in oncology nutrition, alone and in combination with exercise, relative to current evidence and international societies’ recommendations. The panel recommended five principles to optimize clinical oncology practice: (1) position oncology nutrition at the center of multidisciplinary care; (2) partner with colleagues and administrators to integrate a nutrition care process into the multidisciplinary cancer care approach; (3) screen all patients for malnutrition risk at diagnosis and regularly throughout treatment; (4) combine exercise and nutrition interventions before (e.g., prehabilitation), during, and after treatment as oncology standard of care to optimize nutrition status and muscle mass; and (5) incorporate a patient-centered approach into multidisciplinary care.
- Published
- 2021
38. Animal exercise studies in cardiovascular research: Current knowledge and optimal design—A position paper of the Committee on Cardiac Rehabilitation, Chinese Medical Doctors’ Association
- Author
-
Shenghui Lin, Junjie Xiao, Guifu Wu, Yuqin Shen, Yihua Bei, Zhiqing Fan, Lei Wang, Lin Che, Suixin Liu, Wei Gao, Jian Yang, Lan Guo, Xiao Lu, Qi Liang, Guolin Zhang, Wei Zhao, and Rongjing Ding
- Subjects
medicine.medical_specialty ,China ,medicine.medical_treatment ,Cardiovascular health ,Cardiovascular research ,Physical Therapy, Sports Therapy and Rehabilitation ,Disease ,Review ,Basic research ,medicine ,Animals ,Humans ,Orthopedics and Sports Medicine ,Intensive care medicine ,Beneficial effects ,Exercise ,Rehabilitation ,Cardiac Rehabilitation ,business.industry ,Exercise models ,Cardiovascular disease ,Animal studies ,Exercise Therapy ,Cardiovascular Diseases ,GV557-1198.995 ,Sports medicine ,Position paper ,business ,RC1200-1245 ,Sports - Abstract
Highlights • Standard procedures and appropriate assessment of exercise are proposed for the commonly used animal models related to chronic exercise (e.g., treadmill running, voluntary wheel running, swimming exercise, and resistance exercise) in cardiovascular research. • Optimal design of animal exercise studies in cardiovascular research should consider the choice of exercise models, control of exercise protocols, exercise at different stages of disease, and other factors, such as age, sex, and genetic background. • An optimal design for studying exercise-induced physiological cardiac growth and its related beneficial effects against cardiovascular diseases is presented., Growing evidence has demonstrated exercise as an effective way to promote cardiovascular health and protect against cardiovascular diseases However, the underlying mechanisms of the beneficial effects of exercise have yet to be elucidated. Animal exercise studies are widely used to investigate the key mechanisms of exercise-induced cardiovascular protection. However, standardized procedures and well-established evaluation indicators for animal exercise models are needed to guide researchers in carrying out effective, high-quality animal studies using exercise to prevent and treat cardiovascular diseases. In our review, we present the commonly used animal exercise models in cardiovascular research and propose a set of standard procedures for exercise training, emphasizing the appropriate measurements and analysis in these chronic exercise models. We also provide recommendations for optimal design of animal exercise studies in cardiovascular research, including the choice of exercise models, control of exercise protocols, exercise at different stages of disease, and other considerations, such as age, sex, and genetic background. We hope that this position paper will promote basic research on exercise-induced cardiovascular protection and pave the way for successful translation of exercise studies from bench to bedside in the prevention and treatment of cardiovascular diseases., Graphical abstract Image, graphical abstract
- Published
- 2021
39. Clinical nutrition and human rights. An international position paper.
- Author
-
Cardenas, Diana, Correia, Maria Isabel Toulson Davisson, Ochoa, Juan B., Hardy, Gil, Rodriguez-Ventimilla, Dolores, Bermúdez, Charles E., Papapietro, Karin, Hankard, Régis, Briend, André, Ungpinitpong, Winai, Zakka, Katerina Mary, Pounds, Teresa, Cuerda, Cristina, and Barazzoni, Rocco
- Abstract
The International Working Group for Patients' Right to Nutritional Care presents its position paper regarding nutritional care as a human right intrinsically linked to the right to food and the right to health. All people should have access to food and evidence-based medical nutrition therapy including artificial nutrition and hydration. In this regard, the hospitalized malnourished ill should mandatorily have access to screening, diagnosis, nutritional assessment, with optimal and timely nutritional therapy in order to overcome malnutrition associated morbidity and mortality, while reducing the rates of disease-related malnutrition. This right does not imply there is an obligation to feed all patients at any stage of life and at any cost. On the contrary, this right implies, from an ethical point of view, that the best decision for the patient must be taken and this may include, under certain circumstances, the decision not to feed. Application of the human rights-based approach to the field of clinical nutrition will contribute to the construction of a moral, political and legal focus to the concept of nutritional care. Moreover, it will be the cornerstone to the rationale of political and legal instruments in the field of clinical nutrition. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. ANMCO POSITION PAPER: Prognostic and therapeutic relevance of non-obstructive coronary atherosclerosis
- Author
-
Francesco Orso, Serafina Valente, Adriano Murrone, Gabriele Grippo, Stefano Domenicucci, Stefania Angela Di Fusco, Giancarlo Casolo, Maurizio Giuseppe Abrignani, Marco Corda, Michele Massimo Gulizia, Giuseppe Di Tano, Domenico Gabrielli, Daniele Grosseto, Fortunato Scotto di Uccio, and Furio Colivicchi
- Subjects
medicine.medical_specialty ,Cardiovascular risk factors ,Coronary Artery Disease ,Disease ,Coronary angiogram ,Non-obstructive CAD ,Coronary Angiography ,Coronary artery disease ,Risk Factors ,medicine ,Humans ,Relevance (law) ,AcademicSubjects/MED00200 ,Intensive care medicine ,Coronary atherosclerosis ,business.industry ,Articles ,Atherosclerosis ,Prognosis ,medicine.disease ,Coronary arteries ,medicine.anatomical_structure ,Position paper ,Cardiology and Cardiovascular Medicine ,business - Abstract
Atherosclerosis often affects the coronary arterial tree. Frequently the disease does not translate in significant narrowing of the vessels, thus determining only a non-obstructive disease. This condition that is described as non-obstructive coronary artery disease (NobsCAD) should be distinguished from the absence of disease (i.e. smooth coronary arteries) as it carries a specific prognostic value. The detection and reporting of NobsCAD should prompt preventive measures that can be individualized upon the degree of the underlying burden of disease. The accompanying clinical condition, the other cardiovascular risk factors present, and the description of the severity and extent of NobsCAD should provide the framework for an individualized treatment that should also consider the best available scientific evidence and guidelines. The description of NobsCAD represents important information to be collected whenever a coronary angiogram (both invasive and non-invasive) is performed. Treating the patient according to the presence and extent of NobsCAD offers prognostic benefits well beyond those offered by considering only the traditional cardiovascular risk factors. In order to reach this goal, NobsCAD should not be confused with the absence of coronary atherosclerosis or even ignored when detected as if it was a trivial information to provide.
- Published
- 2021
41. ANMCO POSITION PAPER: The reorganization of cardiology in times of the SARS-CoV-2 pandemic
- Author
-
Stefano Urbinati, Nadia Aspromonte, Vincenzo Amodeo, Luigi Tavazzi, Michele Massimo Gulizia, Massimo Imazio, Giuseppe Di Pasquale, Pasquale Caldarola, Manlio Cipriani, Loris Roncon, Domenico Gabrielli, Fortunato Scotto di Uccio, Stefano Domenicucci, Adriano Murrone, Giuseppina Maura Francese, Andrea Di Lenarda, Furio Colivicchi, and Serafina Valente
- Subjects
Telemedicine ,National Health Service ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Cardiology ,COVID-19 ,Articles ,Disease ,medicine.disease ,Phase (combat) ,Health care ,Pandemic ,medicine ,Position paper ,AcademicSubjects/MED00200 ,Medical emergency ,Cardiology and Cardiovascular Medicine ,business ,Organization - Abstract
The COVID-19 pandemic represents an unprecedented event that has brought deep changes in hospital facilities with reshaping of the health system organization, revealing inadequacies of current hospital and local health systems. When the COVID-19 emergency will end, further evaluation of the national health system, new organization of acute wards, and a further evolution of the entire health system will be needed to improve care during the chronic phase of disease. Therefore, new standards for healthcare personnel, more efficient organization of hospital facilities for patients with acute illnesses, improvement of technological approaches, and better integration between hospital and territorial services should be pursued. With experience derived from the COVID-19 pandemic,new models, paradigms, interventional approaches, values and priorities should be suggested and implemented.
- Published
- 2021
42. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
- Author
-
Martin S. Weber, Stefan Bittner, Claudio Gobbi, Hayrettin Tumani, Renaud Du Pasquier, Fedor Heidenreich, Ralf A. Linker, Frank Weber, Michael Platten, Martin Stangel, Andrew T. Chan, Heinz Wiendl, Olaf Hoffmann, Thomas Berger, Christian Enzinger, die Multiple Sklerose Therapie Konsensus Gruppe, Elisabeth Fertl, Mathias Mäurer, Orhan Aktas, Uwe K. Zettl, Ralf Gold, Boris Kallmann, Christoph Kleinschnitz, Florian Deisenhammer, Fritz Leutmezer, Jan D. Lünemann, Volker Limmroth, Zoë R. Hunter, Klaus Gehring, Aiden Haghikia, Verena I. Leussink, Franziska Di Pauli, Martin Berghoff, Michael Guger, Luisa Klotz, Tobias Derfuss, Tjalf Ziemssen, Stephan Schmidt, Uta Meyding-Lamadé, Hans-Peter Hartung, Sven G. Meuth, Frauke Zipp, Karl Baum, Achim Gass, Peter Rieckmann, Adam Czaplinski, Norbert Goebels, and Andreas Lutterotti
- Subjects
0301 basic medicine ,Central Nervous System ,medicine.medical_specialty ,Early therapeutic intervention ,Neurology ,Consensus ,Multiple Sclerosis ,Disease ,Guideline ,Behandlungsempfehlung ,03 medical and health sciences ,0302 clinical medicine ,Germany ,medicine ,Humans ,Intensive care medicine ,Leitlinie ,business.industry ,Multiple sclerosis ,Psychosomatic medicine ,General Medicine ,medicine.disease ,Autoimmune-mediated disease ,Immuntherapie ,Europe ,Psychiatry and Mental health ,030104 developmental biology ,Position paper ,Konsensuspapiere ,Neurology (clinical) ,Neurosurgery ,Psychopharmacology ,Immunotherapy ,business ,Treatment recommendation ,030217 neurology & neurosurgery ,Autoimmunerkrankung ,Frühe Therapieintervention - Abstract
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).Die Multiple Sklerose ist eine komplexe, autoimmun vermittelte Erkrankung des zentralen Nervensystems, charakterisiert durch inflammatorische Demyelinisierung sowie axonalen/neuronalen Schaden. Die Zulassung verschiedener verlaufsmodifizierender Therapien und unser verbessertes Verständnis der Krankheitsmechanismen und -entwicklung in den letzten Jahren haben die Prognose und den Verlauf der Erkrankung deutlich verändert. Diese Aktualisierung der Behandlungsempfehlung der Multiple Sklerose Therapie Konsensus Gruppe konzentriert sich auf die wichtigsten Empfehlungen für verlaufsmodifizierende Therapien der Multiplen Sklerose im Jahr 2021. Unsere Empfehlungen basieren auf aktuellen wissenschaftlichen Erkenntnissen und gelten für diejenigen Medikamente, die in weiten Teilen Europas, insbesondere in den deutschsprachigen Ländern (Deutschland, Österreich, Schweiz), zugelassen sind.
- Published
- 2021
43. ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging
- Author
-
Jochen Walz, Jonathan Richenberg, Tobias Penzkofer, Baris Turkbey, Jelle O. Barentsz, Anwar R. Padhani, Geert Villeirs, Vibeke Løgager, Masoom A. Haider, Valeria Panebianco, Olivier Rouvière, Georg Salomon, Ivo G. Schoots, Henkjan J. Huisman, and Radiology & Nuclear Medicine
- Subjects
Image-Guided Biopsy ,Male ,Artificial intelligence ,COMPUTER-AIDED DETECTION ,PREDICTION ,Disease ,artificial intelligence ,deep learning ,image-guided biopsy ,multiparametric magnetic resonance imaging ,prostate cancer ,Image-guided biopsy ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Multiparametric magnetic resonance imaging ,Medicine and Health Sciences ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Neuroradiology ,PI-RADS ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,Interventional radiology ,Urogenital ,Deep learning ,General Medicine ,PERFORMANCE ,medicine.disease ,Magnetic Resonance Imaging ,Workflow ,Software deployment ,030220 oncology & carcinogenesis ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,BIOPSY ,Position paper ,business ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit ,MRI - Abstract
Abstract Artificial intelligence developments are essential to the successful deployment of community-wide, MRI-driven prostate cancer diagnosis. AI systems should ensure that the main benefits of biopsy avoidance are delivered while maintaining consistent high specificities, at a range of disease prevalences. Since all current artificial intelligence / computer-aided detection systems for prostate cancer detection are experimental, multiple developmental efforts are still needed to bring the vision to fruition. Initial work needs to focus on developing systems as diagnostic supporting aids so their results can be integrated into the radiologists’ workflow including gland and target outlining tasks for fusion biopsies. Developing AI systems as clinical decision-making tools will require greater efforts. The latter encompass larger multicentric, multivendor datasets where the different needs of patients stratified by diagnostic settings, disease prevalence, patient preference, and clinical setting are considered. AI-based, robust, standard operating procedures will increase the confidence of patients and payers, thus enabling the wider adoption of the MRI-directed approach for prostate cancer diagnosis. Key Points • AI systems need to ensure that the benefits of biopsy avoidance are delivered with consistent high specificities, at a range of disease prevalence. • Initial work has focused on developing systems as diagnostic supporting aids for outlining tasks, so they can be integrated into the radiologists’ workflow to support MRI-directed biopsies. • Decision support tools require a larger body of work including multicentric, multivendor studies where the clinical needs, disease prevalence, patient preferences, and clinical setting are additionally defined.
- Published
- 2021
44. Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC)
- Author
-
Pedro Marques-Vidal, Konstantinos C. Koskinas, Jean-Claude Barthélémy, Maryam Kavousi, Delphine De Smedt, Vassilios S. Vassiliou, Charlotta Pisinger, Monica Tiberi, Maja-Lisa Løchen, Demosthenes B. Panagiotakos, and Eva Prescott
- Subjects
medicine.medical_specialty ,Epidemiology ,Disease ,tobacco ,law.invention ,SDG 3 - Good Health and Well-being ,law ,heart rate ,medicine ,Electronic cigarette ,Risk factor ,Intensive care medicine ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,business.industry ,cardiovascular ,blood pressure ,Preventive cardiology ,Premature death ,myocardial infarction ,Position paper ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,Cardiology and Cardiovascular Medicine ,business ,Tobacco product - Abstract
This is a pre-copyedited, author-produced version of an article accepted for publication in European Journal of Preventive Cardiology following peer review. The version of record Kavousi, Pisinger, Barthelemy, Smedt, Koskinas, Marques-Vidal, Panagiotakos, Prescott, Tiberi, Vassiliou, Løchen. Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology (EJPC). 2020:2047487320941993, is available online at: https://doi.org/10.1177/2047487320941993. Background - Tobacco use is the single largest preventable risk factor for premature death of non-communicable diseases and the second leading cause of cardiovascular disease. In response to the harmful effects of tobacco smoking, the use of electronic cigarettes (e-cigarettes) has emerged and gained significant popularity over the past 15 years. E-cigarettes are promoted as safe alternatives for traditional tobacco smoking and are often suggested as a way to reduce or quit smoking. However, evidence suggests they are not harmless. Discussion - The rapid evolution of the e-cigarette market has outpaced the legislator’s regulatory capacity, leading to mixed regulations. The increasing use of e-cigarettes in adolescents and young individuals is of concern. While the long-term direct cardiovascular effects of e-cigarettes remain largely unknown, the existing evidence suggests that the e-cigarette should not be regarded as a cardiovascular safe product. The contribution of e-cigarette use to reducing conventional cigarette use and smoking cessation is complex, and the impact of e-cigarette use on long-term cessation lacks sufficient evidence. Conclusion - This position paper describes the evidence regarding the prevalence of e-cigarette smoking, uptake of e-cigarettes in the young, related legislations, cardiovascular effects of e-cigarettes and the impact of e-cigarettes on smoking cessation. Knowledge gaps in the field are also highlighted. The recommendations from the population science and public health section of the European Association of Preventive Cardiology are presented.
- Published
- 2020
45. Survey on patients’ organisations’ knowledge and position paper on screening for inherited neuromuscular diseases in Europe
- Author
-
F. Lamy, A. Ferlini, ERN EURO-NMD Patient Advisory Board, Teresinha Evangelista, Ecologie Systématique et Evolution (ESE), AgroParisTech-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Association française contre les myopathies (AFM-Téléthon), Università degli Studi di Ferrara (UniFE), Institut de Myologie, Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Gestionnaire, HAL Sorbonne Université 5, and Università degli Studi di Ferrara = University of Ferrara (UniFE)
- Subjects
Newborn screening ,medicine.medical_specialty ,Genetic counseling ,Patient organisations ,lcsh:Medicine ,Genetic Counseling ,Disease ,[SDV.GEN] Life Sciences [q-bio]/Genetics ,Pre-implantation diagnosis ,03 medical and health sciences ,Pre-conception carrier screening ,0302 clinical medicine ,Pregnancy ,Surveys and Questionnaires ,medicine ,Humans ,Pharmacology (medical) ,Asset (economics) ,Genetic Testing ,Genetics (clinical) ,Reimbursement ,Genetic testing ,0303 health sciences ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,medicine.diagnostic_test ,Research ,030305 genetics & heredity ,lcsh:R ,Infant, Newborn ,Prenatal screening ,General Medicine ,3. Good health ,Europe ,Neuromuscular diseases ,Family medicine ,Position paper ,Female ,Psychology ,030217 neurology & neurosurgery ,Qualitative research - Abstract
Background The development of new genetic testing methods and the approval of the first treatments raises questions regarding when and how to perform screening for inherited neuromuscular conditions. Screening directives and access to the different techniques is not uniform across Europe. The patient advisory board of the European reference network for rare neuromuscular diseases (NMD) conducted a qualitative study to understand the state of play of screening for inherited NMD in Europe and patients’ needs. Results We collected answers from 30 patient organisations (POs) from 18 European countries. Fifteen acknowledge the existence of pre-implantation genetic diagnosis in their country. Regarding prenatal screening, we had 25 positive answers and 5 negative ones. Twenty-four POs mentioned that newborn screening was available in their country. We had some contradictory answers from POs from the same country and in some cases; diseases said to be part of the screening programmes were not hereditary disorders. Twenty-eight organisations were in favour of screening tests. The reasons for the two negative answers were lack of reimbursement and treatment, religious beliefs and eventual insurance constrains. Most POs (21) were in favour of systematic screening with the option to opt-out. Regarding the timing for screening, “at birth”, was the most consensual response. The main priority to perform screening for NMDs was early access to treatment, followed by shorter time to diagnostic, preventive care and genetic counselling. Conclusions This is the first study to assess knowledge and needs of POs concerning screening for NMDs. The knowledge of POs regarding screening techniques is quite uneven. This implies that, even in communities highly motivated and knowledgeable of the conditions they advocate for, there is a need for better information. Differences in the responses to the questions “how and when to screen” shows that the screening path depends on the disease and the presence of a disease modifying treatment. The unmet need for screening inherited NMDs should follow an adaptive pathway related to the fast moving medical landscape of NMDs. International coordination leading to a common policy would certainly be a precious asset tending to harmonize the situation amongst European countries.
- Published
- 2021
46. An Imbalance of the Immune System Instead of a Disease Behind Marginal Bone Loss Around Oral Implants: Position Paper
- Author
-
Pentti Tengvall, Tomas Albrektsson, Christer Dahlin, David Reinedahl, Ann Wennerberg, and Ricardo Trindade
- Subjects
Dental Implants ,Titanium ,business.industry ,05 social sciences ,Alveolar Bone Loss ,Dentistry ,Implant failure ,030206 dentistry ,General Medicine ,Disease ,Bone Diseases, Metabolic ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Dental Prosthesis Design ,Immune System ,0502 economics and business ,Humans ,Position paper ,Medicine ,050211 marketing ,Oral Surgery ,business - Abstract
The purpose of this paper is to present evidence that supports the notion that the primary reason behind marginal bone loss and implant failure is immune-based and that bacterial actions in the great majority of problematic cases are of a secondary nature.The paper is written as a narrative review.Evidence is presented that commercially pure titanium is not biologically inert, but instead activates the innate immune system of the body. For its function, the clinical implant is dependent on an immune/inflammatory defense against bacteria. Biologic models such as ligature studies have incorrectly assumed that the primary response causing marginal bone loss is due to bacterial action. In reality, bacterial actions are secondary to an imbalance of the innate immune system caused by the combination of titanium implants and ligatures, ie, nonself. This immunologic imbalance may lead to marginal bone resorption even in the absence of bacteria.Marginal bone loss and imminent oral implant failure cannot be properly analyzed without a clear understanding of immunologically caused tissue responses.
- Published
- 2020
47. A paper-based SERS assay for sensitive duplex cytokine detection towards the atherosclerosis-associated disease diagnosis
- Author
-
Xiaoyan Zhou, Chunxia Li, Yuan Liu, and Yuling Wang
- Subjects
Paper ,Chemokine ,biology ,Surface Properties ,Chemistry ,medicine.medical_treatment ,Biomedical Engineering ,Metal Nanoparticles ,General Chemistry ,General Medicine ,Disease ,Computational biology ,Paper based ,Atherosclerosis ,Spectrum Analysis, Raman ,Cytokine ,Immune system ,Duplex (building) ,medicine ,biology.protein ,Cytokines ,Humans ,General Materials Science ,Gold ,Particle Size - Abstract
Atherosclerosis (AS) is the most common factor causing many cardiovascular and cerebrovascular diseases and has received considerable attention. The occurrence mechanism of AS is uncertain because it is a choronically pathological process that is influenced by multi-aspects, among which cytokines play the key roles in regulating the processes of the immune system. For example, two key cytokines, namely, IL-10 and MCP-1 (chemokine), which are involved in AS progression with varied levels, can be used for AS status monitoring and early diagnosis of AS-associated diseases. Hence, a new paper-based, surface-enhanced Raman spectroscopy (SERS) sensing platform was established for the detection of these two key cytokines. By combining a nanoporous networking membrane as the substrate and SERS nanotags as the probe for signal reading, together with a sandwich design, sensitive and specific identification and quantification of cytokine targets in human serum were achieved with excellent sensing characteristics. The lowest detectable concentration was determined to be 0.1 pg mL-1 for both IL-10 and MCP-1 in human serum. The assay also exhibits high specificity towards target cytokine detection, with low-nonspecific binding and acceptable cross-reactivity in the presence of other structurally similar targets. Finally, the practicability was validated by performing duplex detection in human serum, which further demonstrates the high specificity of the assay for the detection of target cytokines. Taken together, these promising results illustrate that this developed sensing assay is a candidate for clinical multi-target analysis in real environments.
- Published
- 2020
48. Telemetry System for Diagnosis of Asthma and Chronical Obstructive Pulmonary Disease (COPD)
- Author
-
Granulo, Eldar, Bećar, Lejla, Gurbeta, Lejla, Badnjević, Almir, Akan, Ozgur, Series editor, Bellavista, Paolo, Series editor, Cao, Jiannong, Series editor, Coulson, Geoffrey, Series editor, Dressler, Falko, Series editor, Ferrari, Domenico, Series editor, Gerla, Mario, Series editor, Kobayashi, Hisashi, Series editor, Palazzo, Sergio, Series editor, Sahni, Sartaj, Series editor, Shen, Xuemin (Sherman), Series editor, Stan, Mircea, Series editor, Xiaohua, Jia, Series editor, Zomaya, Albert Y., Series editor, Ahmed, Mobyen Uddin, editor, Begum, Shahina, editor, and Raad, Wasim, editor
- Published
- 2016
- Full Text
- View/download PDF
49. Cardiovascular disease and COVID-19:a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)
- Author
-
Maria Dorobantu, Dirk J. Duncker, Geneviève Derumeaux, Diana A. Gorog, Zorana Vasiljevic-Pokrajcic, Cor de Wit, Marija Vavlukis, Dimitris Tousoulis, Etto C. Eringa, Edina Cenko, Christian Hassager, Davor Miličić, Teresa Padró, Giuseppe De Luca, Gemma Vilahur, Marc J. Claeys, Lina Badimon, Danijela Trifunovic-Zamaklar, Raffaele Bugiardini, Frank R. Heinzel, Olivia Manfrini, Evangelos Oikonomou, Kurt Huber, RS: Carim - H08 Experimental atrial fibrillation, Fysiologie, Physiology, ACS - Diabetes & metabolism, Cenko E., Badimon L., Bugiardini R., Claeys M.J., De Luca G., de Wit C., Derumeaux G., Dorobantu M., Duncker D.J., Eringa E.C., Gorog D.A., Hassager C., Heinzel F.R., Huber K., Manfrini O., Milicic D., Oikonomou E., Padro T., Trifunovic-Zamaklar D., Vasiljevic-Pokrajcic Z., Vavlukis M., Vilahur G., and Tousoulis D.
- Subjects
Physiology ,Disease ,Review ,CORONAVIRUS ,030204 cardiovascular system & hematology ,Bioinformatics ,endothelial dysfunction ,0302 clinical medicine ,cytokine ,Cardiometabolic Risk Factor ,thrombosi ,AcademicSubjects/MED00200 ,030212 general & internal medicine ,Endothelial dysfunction ,CARDIOLOGY ,Clinical Trials as Topic ,Sex Characteristics ,post-acute COVID-19 ,THROMBOEMBOLISM FOLLOWING HOSPITALIZATION ,Inflammation/complications ,Cardiovascular disease ,Thrombosis ,Pathophysiology ,3. Good health ,Cardiovascular Diseases ,Myocardial injury ,Cardiovascular Diseases/enzymology ,COVID-19/complications ,Angiotensin-Converting Enzyme 2 ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Infection ,Viral load ,POSITION PAPER ,Human ,ANGIOTENSIN-CONVERTING ENZYME ,EXPRESSION ,SEX-DIFFERENCES ,microcirculation ,Inflammation ,Angiotensin-Converting Enzyme 2/metabolism ,03 medical and health sciences ,Post-Acute COVID-19 Syndrome ,SDG 3 - Good Health and Well-being ,Physiology (medical) ,medicine ,Humans ,thrombosis ,business.industry ,SARS-CoV-2 ,INFLAMMATORY RESPONSE ,Cardiometabolic Risk Factors ,COVID-19 ,medicine.disease ,CARDIAC ARREST SYNDROME ,cytokines ,inflammation ,Cardiovascular Injury ,Myocardial fibrosis ,Human medicine ,business - Abstract
The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory and immune responses are characteristic features of severe COVID-19. Pre-existing cardiovascular disease and viral load are linked to myocardial injury and worse outcomes. The vascular response to cytokine production and the interaction between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and angiotensin-converting enzyme 2 receptor may lead to a significant reduction in cardiac contractility and subsequent myocardial dysfunction. In addition, a considerable proportion of patients who have been infected with SARS-CoV-2 do not fully recover and continue to experience a large number of symptoms and post-acute complications in the absence of a detectable viral infection. This conditions often referred to as ‘post-acute COVID-19’ may have multiple causes. Viral reservoirs or lingering fragments of viral RNA or proteins contribute to the condition. Systemic inflammatory response to COVID-19 has the potential to increase myocardial fibrosis which in turn may impair cardiac remodelling. Here, we summarize the current knowledge of cardiovascular injury and post-acute sequelae of COVID-19. As the pandemic continues and new variants emerge, we can advance our knowledge of the underlying mechanisms only by integrating our understanding of the pathophysiology with the corresponding clinical findings. Identification of new biomarkers of cardiovascular complications, and development of effective treatments for COVID-19 infection are of crucial importance., Graphical Abstract Graphical Abstract
- Published
- 2021
50. Paper-based ELISA diagnosis technology for human brucellosis based on a multiepitope fusion protein
- Author
-
Han Li, Hai Jiang, Mingjun Sun, Qiongqiong Bai, Dehui Yin, Jingpeng Zhang, Xiling Wu, and Jihong Shao
- Subjects
Bacterial Diseases ,Serum Proteins ,B Cells ,RC955-962 ,Disease ,Pathology and Laboratory Medicine ,Biochemistry ,Epitope ,Cell Fusion ,Epitopes ,White Blood Cells ,Medical Conditions ,Filter Paper ,Animal Cells ,Zoonoses ,Arctic medicine. Tropical medicine ,Medicine and Health Sciences ,Enzyme-Linked Immunoassays ,biology ,Bacterial Pathogens ,Laboratory Equipment ,medicine.anatomical_structure ,Infectious Diseases ,Medical Microbiology ,Engineering and Technology ,Pathogens ,Cellular Types ,Public aspects of medicine ,RA1-1270 ,Bacterial Outer Membrane Proteins ,Research Article ,Neglected Tropical Diseases ,China ,Cell Physiology ,Immune Cells ,Immunology ,Equipment ,Enzyme-Linked Immunosorbent Assay ,Brucella ,Research and Analysis Methods ,Sensitivity and Specificity ,Microbiology ,Brucellosis ,Antigen ,Diagnostic Medicine ,medicine ,Humans ,Immunoassays ,Antibody-Producing Cells ,Microbial Pathogens ,B cell ,Antigens, Bacterial ,Blood Cells ,Bacteria ,business.industry ,Public Health, Environmental and Occupational Health ,Organisms ,Biology and Life Sciences ,Proteins ,Cell Biology ,medicine.disease ,biology.organism_classification ,Tropical Diseases ,Fusion protein ,Virology ,Infectious disease (medical specialty) ,Immunologic Techniques ,business - Abstract
Background Brucellosis, as a serious zoonotic infectious disease, has been recognized as a re-emerging disease in the developing countries worldwide. In china, the incidence of brucellosis is increasing each year, seriously threatening the health of humans as well as animal populations. Despite a quite number of diagnostic methods currently being used for brucellosis, innovative technologies are still needed for its rapid and accurate diagnosis, especially in area where traditional diagnostic is unavailable. Methodology/Principal findings In this study, a total of 22 B cell linear epitopes were predicted from five Brucella outer membrane proteins (OMPs) using an immunoinformatic approach. These epitopes were then chemically synthesized, and with the method of indirect ELISA (iELISA), each of them displayed a certain degree of capability in identifying human brucellosis positive sera. Subsequently, a fusion protein consisting of the 22 predicted epitopes was prokaryotically expressed and used as diagnostic antigen in a newly established brucellosis testing method, nano-ZnO modified paper-based ELISA (nano-p-ELISA). According to the verifying test using a collection of sera collected from brucellosis and non-brucellosis patients, the sensitivity and specificity of multiepitope based nano-p-ELISA were 92.38% and 98.35% respectively. The positive predictive value was 98.26% and the negative predictive value was 91.67%. The multiepitope based fusion protein also displayed significantly higher specificity than Brucella lipopolysaccharide (LPS) antigen. Conclusions B cell epitopes are important candidates for serologically testing brucellosis. Multiepitope fusion protein based nano-p-ELISA displayed significantly sensitivity and specificity compared to Brucella LPS antigen. The strategy applied in this study will be helpful to develop rapid and accurate diagnostic method for brucellosis in human as well as animal populations., Author summary Brucellosis is one of the most important zoonosis in the world and has caused tremendous economic losses in agriculture and animal husbandry in many countries. Developing rapid, sensitive and specific diagnostic methods is very important for early detection and treatment of brucellosis patients. In this study, a novel diagnostic technique, nano-ZnO modified paper ELISA, was established. The antigen used in this technique was a fusion protein containing multiple B cell epitopes, which were predicted from Brucella major outer membrane proteins such as Bp26, Omp31, Omp16, Omp2b and Omp25. Comparing to traditional LPS antigen, this multiepitope based antigen displayed considerably higher sensitivity and higher specificity in laboratory. With the strategy described in this paper, more efficient epitopes and protein antigen can be identified in the future. Currently, LPS antigen is only prepared from live Brucella, while protein antigen can be produced in large quantities in prokaryotic expression system. In addition to nano-p-ELISA, this protein antigen can also be used for development other methods such as fluorescent polarization assay (FPA) and immunochromatographic assay (ICA) to meet the varied demand for brucellosis testing.
- Published
- 2021
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.